{
  "docId": "019de076-7d6c-774e-85e8-ffe50da37251",
  "docSlug": "0b0d701714d17efa78c23c196990e90c",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 37,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Uses a pyramid diagram to represent the progression of clinical validation.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-7d6c-774e-85e8-ffe50da37251/8",
  "deckHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251",
  "deckJsonHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251.json",
  "deckAnchorHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.52,
        "x": 0.45,
        "y": 0.13
      },
      "kind": "diagram",
      "text": "Pyramid showing progression from Clinical Advantages to Phase 1b/2 results to Best-in-Class potential",
      "attrs": null,
      "subkind": "pyramid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0077412e-4974-425c-9a0f-7399a25d555f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.04,
        "y": 0.63
      },
      "kind": "list",
      "text": "Limitations of 1st Gen Viruses: Commercial/Late-stage 1st Generation viruses confirm modality's potential; Limited to local delivery and scope of addressable cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc9f01fe-6ecf-4cf1-aea7-0027597d1a49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "table",
      "text": "AMGEN (FDA/EMA Approval in Melanoma), Daiichi-Sankyo (PMDA Approval in malignant glioma), CG Oncology (Phase 3 monotherapy trial in bladder cancer)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "372aa253-20c5-4474-aff0-606468550973",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "A Maturing Modality with Phase 3 Companies validating OV Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e89b677e-08ca-4196-82ca-f7cc205141a2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "pyramid",
      "slug": null,
      "matchId": "82c24830-cf48-405a-976d-09c538ac11f4",
      "evidence": "Visual hierarchy of clinical validation",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}